238 related articles for article (PubMed ID: 23842448)
1. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
2. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
5. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
6. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
8. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
10. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
11. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
12. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
13. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
15. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
17. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
Peng KW; Myers R; Greenslade A; Mader E; Greiner S; Federspiel MJ; Dispenzieri A; Russell SJ
Gene Ther; 2013 Mar; 20(3):255-61. PubMed ID: 22476202
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
Ammayappan A; Peng KW; Russell SJ
J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
[TBL] [Abstract][Full Text] [Related]
19. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
20. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]